Specialty Pharmacy

Sanofi and Regeneron Pharmaceuticals announce results of phase 3 trial showing efficacy of sarilumab in improving the signs and symptoms of active rheumatoid arthritis.

New proposed plan designs would give first-dollar coverage for all prescription drugs in the silver and gold plans.

Most read articles of the week on Specialty Pharmacy Times.

The cost of treating pediatric cancer can force higher-income families into poverty.

Harnessing T cells may lead to significant new cancer treatments.

MiRNA is a small non-coding RNA molecule that plays a role in the regulation of gene expression.

Beaming of X-rays at immobilized molecules could lead to new methods to fight HIV and retrovirus-based cancers.

Researchers evaluate fingolimod (Gilenya) in patients with highly active relapsing remitting multiple sclerosis.

Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

Average percentage of covered drugs with coinsurance jumped from 35% in 2014 to 58% in 2016, leading to higher out-of-pocket costs.

Electronic health records and e-prescribing allow for electronic refill submissions to ease the burden on care providers.

New approach could prevent bone loss induced by antiretroviral therapy in HIV patients.

Obesity carries increased risk for diabetes, cardiovascular disease, and lymphomas.

Cancer drug called nutlins activate the P53 gene to trigger blood cancer cell death instead of temporarily suppressing the disease.

Combination of metformin and pioglitazone shows a significant decrease in the number of new or enlarging brain lesions in MS patients.

Foods with a high glycemic index raise blood sugar levels and stimulate the production of insulin

The American Journal of Health-Systems Pharmacists recently published an update to its guidelines on pharmacist involvement in HIV care.

Study finds Affordable Care Act marektplace enrollment must grow to keep premiums stable and to remain attractive to insurers.

Idelvion offers high level protection for up to 14-day dosing for hemophilia B.

Proposal seeks to evaluate new incentives that drive the most effective drugs to be prescribed with a new payment approach.

Proposal will evaluate different physician and patient incentives that drive the most effective drugs to be prescribed with a new payment model.

Idelvion is the first and only factor IX therapy that gives high level protection for up to 14-day dosing for hemophilia B.

Approximately 2.3 million people worldwide are infected with both HIV and hepatitis C virus.

Signaling pathway may be vital in treating colorectal cancer patients.

Green tea loses its potential in IBD as an antioxidant after a meal rich in iron.

Researchers evaluate the link between vitamin D and multiple sclerosis development.

Three facts pharmacists need to new about the development of new biosimilar medications.

Major breakthroughs in hepatitis C virus research hold promise for patient care and control of viral global health crises.

The day-to-day struggle of a mom dealing with the symptoms of multiple sclerosis.

Keytruda showed an improvement in overall survival compared with chemotherapy in patients with NSCLC.